{"id":"W2029712223","doi":"10.1038/bjc.2012.21","title":"A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Medical Association","funders":"National Cancer Institute; Moffitt Cancer Center","keywords":"Carboplatin; Medicine; Etoposide; Adverse effect; Clinical endpoint; Internal medicine; Chemotherapy; Anesthesia; Clinical trial; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001037091,0.001349071,0.00172314,0.0003047443,0.0004221395,0.0007557127,0.0008832167,0.001055568,0.002846224],"category_scores_gemma":[0.0006420852,0.0004217431,0.0008828313,0.0003809687,0.001041541,0.0006582772,0.0003162131,0.002918791,0.0005693796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007657891,"about_ca_system_score_gemma":0.00167819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008186128,"about_ca_topic_score_gemma":0.002172694,"domain_scores_codex":[0.9997907,0.00009101321,0.00001262361,0.00003988765,0.00001628981,0.00004944632],"domain_scores_gemma":[0.9992409,0.0001149034,0.0001481824,0.00004262581,0.00003311767,0.0004203479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8351381,0.05843259,0.005506434,0.0006827248,0.0008304688,0.0002557126,0.0002688062,0.002390564,0.03671749,0.0001787124,0.002114845,0.0574834],"study_design_scores_gemma":[0.5412202,0.4461374,0.007096237,0.00002774328,0.0002798927,0.0002201704,0.00004974303,0.0009497427,0.002804885,0.0001314545,0.001063605,0.00001893005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963898,0.000935317,0.0002054499,0.0001800064,0.00005409254,0.001224365,0.0002560059,0.00003804154,0.0007169355],"genre_scores_gemma":[0.9935507,0.001168429,0.0009282873,0.000471891,0.0001088757,0.001632547,0.0009202415,0.0000152924,0.001203878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002846224,"threshold_uncertainty_score":0.009521544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02277835739252881,"score_gpt":0.3474266205460649,"score_spread":0.3246482631535361,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}